Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 4 (2007), Issue 11 (November)

1. Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils.
   Cancer Res, 67(21): 10501-10. [Abstract] [Full-text]
2. Incidence of new tumor formation in patients with hereditary retinoblastoma treated with primary systemic chemotherapy: is there a preventive effect?
   Ophthalmology, 114(11): 2077-82. [Abstract] [Full-text]
3. Temperature-sensitive hydrogels with SiO2-Au nanoshells for controlled drug delivery.
   J Control Release, 123(3): 219-27. [Abstract] [Full-text]
4. 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease.
   J Control Release, 123(3): 211-8. [Abstract] [Full-text]
5. Conjugation of poorly absorptive drugs with mucoadhesive polymers for the improvement of oral absorption of drugs.
   J Control Release, 123(3): 195-202. [Abstract] [Full-text]
6. Serum insensitive, intranuclear protein delivery by the multipurpose cationic lipid SAINT-2.
   J Control Release, 123(3): 228-38. [Abstract] [Full-text]
7. Developmental toxicity of low generation PAMAM dendrimers in zebrafish.
   Toxicol Appl Pharmacol, 225(1): 70-9. [Abstract] [Full-text]
8. Improving the prognosis of patients after radical cystectomy. Part II: the role of perioperative chemotherapy.
   BJU Int, 100(6): 1225-8. [Abstract] [Full-text]
9. Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies.
   Biomaterials, 29(2): 215-27. [Abstract] [Full-text]
10. Nanocarriers.
    Pharm Res, 24(12): 2333-4. [Abstract] [Full-text]
11. Multifunctional nanoparticulate polyelectrolyte complexes.
    Pharm Res, 24(12): 2353-69. [Abstract] [Full-text]
12. Preclinical and clinical in vitro in vivo correlation of an hGH dextran microsphere formulation.
    Pharm Res, 24(12): 2239-48. [Abstract] [Full-text]
13. Enhancement of the solubility and efficacy of poorly water-soluble drugs by hydrophobically-modified polysaccharide derivatives.
    Pharm Res, 24(12): 2317-26. [Abstract] [Full-text]
14. Stability in plasmas of various species of HPMA copolymer-PGE1 conjugates.
    Pharm Res, 24(12): 2270-80. [Abstract] [Full-text]
15. Chemical groups that adhere to the surfaces of living malignant cells.
    Pharm Res, 24(12): 2370-80. [Abstract] [Full-text]
16. One-step surface modification of poly(lactide-co-glycolide) microparticles with heparin.
    Pharm Res, 24(12): 2381-93. [Abstract] [Full-text]
17. Nail swelling as a pre-formulation screen for the selection and optimisation of ungual penetration enhancers.
    Pharm Res, 24(12): 2207-12. [Abstract] [Full-text]
18. Alginate/chitosan nanoparticles are effective for oral insulin delivery.
    Pharm Res, 24(12): 2198-206. [Abstract] [Full-text]
19. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
    J Natl Cancer Inst, 99(21): 1613-22. [Abstract] [Full-text]
20. HIV-1 infection of monocytes is directly related to the success of HAART.
    Virology, 369(1): 35-46. [Abstract] [Full-text]
21. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
    N Engl J Med, 357(19): 1916-27. [Abstract] [Full-text]
22. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP.
    Jpn J Clin Oncol, 37(10): 775-81. [Abstract] [Full-text]
23. Partial remission of a newly diagnosed diffuse large B-cell Non-Hodgkin's lymphoma in a hemodialysis patient after administration of immuno-chemotherapy with rituximab-CHOP.
    Int J Lab Hematol, 29(6): 469-73. [Abstract] [Full-text]
24. Fatal errors in nitrous oxide delivery.
    Anaesthesia, 62(12): 1202-6. [Abstract] [Full-text]
25. Memory effects of monolayers and vesicles formed by the non-ionic surfactant, 2C(18)E(12).
    J Colloid Interface Sci, 316(2): 741-50. [Abstract] [Full-text]
26. The gene for cobalamin-independent methionine synthase is essential in Candida albicans: a potential antifungal target.
    Arch Biochem Biophys, 467(2): 218-26. [Abstract] [Full-text]
27. A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.
    J Urol, 178(6): 2378-83; discussion 2383-4. [Abstract] [Full-text]
28. Bone healing process in critical-sized defects by rhBMP-2 using poloxamer gel and collagen sponge as carriers.
    Micron, 39(1): 17-24. [Abstract] [Full-text]
29. Use of nanocarriers for transdermal vaccine delivery.
    Clin Pharmacol Ther, 82(6): 641-3. [Abstract] [Full-text]
30. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study".
    Eur J Vasc Endovasc Surg, 34(6): 723-9; discussion 730. [Abstract] [Full-text]
31. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery.
    Cancer Res, 67(22): 10958-65. [Abstract] [Full-text]
32. Gabapentin: a multimodal perioperative drug?
    Br J Anaesth, 99(6): 775-86. [Abstract] [Full-text]
33. The latest options and future agents for treating male hypogonadism.
    Expert Opin Pharmacother, 8(17): 2991-3008. [Abstract] [Full-text]
34. High-dose chemotherapy with peripheral blood progenitor cell support for patients with non-small cell lung cancer: the experience of the European Group for Bone Marrow Transplantation (EBMT) Solid Tumours Working Party.
    Bone Marrow Transplant, 40(11): 1045-8. [Abstract] [Full-text]
35. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients.
    Bone Marrow Transplant, 40(11): 1019-25. [Abstract] [Full-text]
36. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer.
    J Clin Oncol, 25(33): 5233-9. [Abstract] [Full-text]
37. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
    J Clin Oncol, 25(33): 5225-32. [Abstract] [Full-text]
38. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    J Clin Oncol, 25(33): 5172-9. [Abstract] [Full-text]
39. Characterization of bone marrow lymphoid infiltrates after immunochemotherapy for follicular lymphoma.
    Am J Clin Pathol, 128(6): 974-80. [Abstract] [Full-text]
40. Photochemically enhanced delivery of a cell-penetrating peptide nucleic acid conjugate targeting human telomerase reverse transcriptase: effects on telomere status and proliferative potential of human prostate cancer cells.
    Cell Prolif, 40(6): 905-20. [Abstract] [Full-text]
41. Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor.
    Circulation, 116(21): 2427-34. [Abstract] [Full-text]
42. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
    J Clin Oncol, 25(33): 5210-7. [Abstract] [Full-text]
43. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme.
    J Control Release, 124(3): 163-71. [Abstract] [Full-text]
44. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.
    J Clin Oncol, 25(33): 5313-8. [Abstract] [Full-text]
45. Dendrimer/DNA complexes encapsulated in a water soluble polymer and supported on fast degrading star poly(DL-lactide) for localized gene delivery.
    J Control Release, 124(3): 181-8. [Abstract] [Full-text]
46. Histopathological findings in postmortem eyes after photodynamic therapy for choroidal neovascularisation in age-related macular degeneration: report of two cases.
    Br J Ophthalmol, 91(12): 1602-6. [Abstract] [Full-text]
47. Stem cell properties and the side population cells as a target for interferon-alpha in adult T-cell leukemia/lymphoma.
    Biochem Biophys Res Commun, 364(4): 808-14. [Abstract] [Full-text]
48. Are alpha9alpha10 nicotinic acetylcholine receptors a pain target for alpha-conotoxins?
    Mol Pharmacol, 72(6): 1406-10. [Abstract] [Full-text]
49. A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer.
    Cancer Chemother Pharmacol, 61(2): 315-21. [Abstract] [Full-text]
50. Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
    Cancer Chemother Pharmacol, 61(2): 309-13. [Abstract] [Full-text]
51. A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
    Cancer Chemother Pharmacol, 61(2): 275-81. [Abstract] [Full-text]
52. Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
    Cancer Chemother Pharmacol, 61(2): 283-9. [Abstract] [Full-text]
53. Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO.
    Cancer Chemother Pharmacol, 61(2): 243-50. [Abstract] [Full-text]
54. Hippocampal volumes are larger in postmenopausal women using estrogen therapy compared to past users, never users and men: a possible window of opportunity effect.
    Neurobiol Aging, 29(1): 95-101. [Abstract] [Full-text]
55. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
    N Engl J Med, 357(21): 2133-42. [Abstract] [Full-text]
56. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    N Engl J Med, 357(21): 2123-32. [Abstract] [Full-text]
57. Growth Hormone (GH) receptor C.1319 G>T polymorphism, but not exon 3 retention or deletion is associated with better first-year growth response to GH therapy in patients with GH deficiency.
    Pediatr Res, 62(6): 735-40. [Abstract] [Full-text]
58. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer.
    Br J Surg, 94(12): 1468-76. [Abstract] [Full-text]
59. Prospective cohort comparison of neoadjuvant chemoradiotherapy versus chemotherapy in patients with oesophageal cancer.
    Br J Surg, 94(12): 1509-14. [Abstract] [Full-text]
60. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials.
    Am Heart J, 154(6): 1085.e1-6. [Abstract] [Full-text]
61. Hepatic-targeting microcapsules construction by self-assembly of bioactive galactose-branched polyelectrolyte for controlled drug release system.
    J Colloid Interface Sci, 317(2): 477-84. [Abstract] [Full-text]
62. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
    Am J Kidney Dis, 50(6): 989-1000. [Abstract] [Full-text]
63. Cardiac risk factors for dental procedures: knowledge among dental practitioners in Wales.
    Br Dent J, 203(10): E21; discussion 590-1. [Abstract] [Full-text]
64. Outcomes in childhood AML in the absence of transplantation in first remission--Children's Cancer Group (CCG) studies 2891 and CCG 213.
    Pediatr Blood Cancer, 50(1): 9-16. [Abstract] [Full-text]
65. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
    Pediatr Blood Cancer, 50(1): 33-6. [Abstract] [Full-text]
66. Treatment of pediatric non-Hodgkin lymphomas in a country with limited resources: results of the first national protocol in Nicaragua.
    Pediatr Blood Cancer, 50(1): 148-52. [Abstract] [Full-text]
67. Stage III cystic partially differentiated nephroblastoma recurring after nephrectomy and chemotherapy.
    Pediatr Blood Cancer, 50(1): 129-31. [Abstract] [Full-text]
68. Long-term remission of children with relapsed and secondary anaplastic large cell non-Hodgkin lymphoma (ALCL) following treatment with pulsed dexamethasone and low dose etoposide.
    Pediatr Blood Cancer, 50(1): 126-9. [Abstract] [Full-text]
69. Treatment of metastatic sialoblastoma with chemotherapy and surgery.
    Pediatr Blood Cancer, 50(1): 134-7. [Abstract] [Full-text]
70. Combination of caregiving stress and hormone replacement therapy is associated with prolonged platelet activation to acute stress among postmenopausal women.
    Psychosom Med, 69(9): 910-7. [Abstract] [Full-text]
71. Is thrombolysis or surgery the best option for acute prosthetic valve thrombosis?
    Interact Cardiovasc Thorac Surg, 6(6): 806-11. [Abstract] [Full-text]
72. Clinical trial: The effect of somatostatin vs. octreotide in preventing post-endoscopic increase in hepatic venous pressure gradient in cirrhotics with bleeding varices.
    Aliment Pharmacol Ther, 26(11): 1479-87. [Abstract] [Full-text]
73. Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes.
    Int J Cancer, 122(2): 452-60. [Abstract] [Full-text]
74. The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: the EXPERT Study.
    Anesth Analg, 105(6): 1540-7, table of contents. [Abstract] [Full-text]
75. Failure of chemoprophylaxis with standard antituberculosis agents in child contacts of multidrug-resistant tuberculosis cases.
    Pediatr Infect Dis J, 26(12): 1142-6. [Abstract] [Full-text]
76. Influence of volume therapy with a modern hydroxyethylstarch preparation on kidney function in cardiac surgery patients with compromised renal function: a comparison with human albumin.
    Crit Care Med, 35(12): 2740-6. [Abstract] [Full-text]
77. A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
    Anticancer Drugs, 19(1): 77-84. [Abstract] [Full-text]
78. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group.
    J Clin Oncol, 25(34): 5442-7. [Abstract] [Full-text]
79. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients.
    J Clin Oncol, 25(34): 5426-34. [Abstract] [Full-text]
80. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
    J Clin Oncol, 25(34): 5410-7. [Abstract] [Full-text]
81. Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life.
    J Clin Oncol, 25(34): 5403-9. [Abstract] [Full-text]
82. Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299.
    J Clin Oncol, 25(34): 5397-402. [Abstract] [Full-text]
83. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.
    J Clin Oncol, 25(34): 5458-64. [Abstract] [Full-text]
84. Integrated approach to designing growth factor delivery systems.
    FASEB J, 21(14): 3896-903. [Abstract] [Full-text]
85. Cancer stem cell: target for anti-cancer therapy.
    FASEB J, 21(14): 3777-85. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.